Inventors and founders of Lytix Biopharma in NRK’s Schrödingers Katt. Watch the programme in Norwegian.

Novel antimicrobial and cancer drugs

Lytix Biopharma AS is a privately-owned pharmaceutical company developing novel antimicrobial peptide-based drugs for the treatment of resistant bacterial and fungal infections, as well as first-in-class oncology treatments.

Shareholder meetings

Lytix Biopharma has scheduled ordinary general assembly on June 8th 2012 in Tromsø. Information in Norwegian ►

Lytix Biopharma recently held shareholder meetings. If you were unable to attend and wish to receive more information, please contact us. Information in Norwegian ►

Lytix Biopharma is hiring

►Manager of Regualtory Affairs and Quality Assurance

Meet Lytix Biopharma

ASCO
The American Society of Clinical Oncology (ASCO) annual meeting in Chicago, May 31 – June 5 2012.

Please send request to post@lytixbiopharma.com to schedule a meeting with representatives from the company.

Unni Hjelmaas, new CEO of Lytix Biopharma AS
Unni Hjelmaas
Unni Hjelmaas

...Unni Hjelmaas has been appointed new CEO of the company. Her current position is General Manager for Roche Norway, and she joins Lytix Biopharma on April 1st. 2012... ►Read more
Tromsø/Oslo, May 15, 2012:
- Lytix Biopharma announces procedures for shareholder information
Read more
Tromsø, May 07, 2012:
- Lytix Biopharma innkaller til ordinær generalforsamling
Read more
Oslo/Tromsø, April 17, 2012:
- Lytix Biopharma arrangerer aksjonærmøter i Oslo 18 april, Harstad 23 april og Tromsø 24 ...
Read more
Tromsø/Oslo, February 28, 2012:
- Unni Hjelmaas, new CEO of Lytix Biopharma AS
Read more
Go to news archive >